Goode Paul's Form 4 filing
Glucotrack, Inc. (GCTK) · filed Mar 28, 2025
- Accession no.
- 0001474506-25-000069
- Filed
- Mar 28, 2025, 9:43 PM ET
- Trade date
- Jun 14, 2024-Mar 12, 2025
- Filing delay
- 287 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 7 derivative transactions. It was filed 287 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Goode PaulCIK 0001622251 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 14, 2024 | Common Stock, par value $0.001 per share | CConversionAcquired | +796 | $31.20 | +$24,835.2 | 2,054 | Direct | |
| Feb 5, 2025 | Common Stock, par value $0.001 per share | JOtherAcquired | +1,500 | –F8 | – | 3,554 | Direct | |
| Mar 12, 2025 | Common Stock, par value $0.001 per share | XIn-the-money exerciseAcquired | +15,435 | $0.00 | $0 | 18,989 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 14, 2024 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +3,277 | $0.00 | $0 | 3,277 | Direct | |
| Jul 1, 2024 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +2,100 | –F2 | – | 2,100 | Direct | |
| Jul 18, 2024 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +321 | $10,000.00 | – | – | Direct | |
| Nov 14, 2024 | Common Stock, par value $0.001 per share | CConversionDisposed | −796 | $24,831.00 | – | – | Direct | Price outlier |
| Nov 14, 2024 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +796 | –F6 | – | 796 | Direct | |
| Nov 14, 2024 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +15,435 | –F6 | – | 796 | Direct | |
| Mar 12, 2025 | Common Stock, par value $0.001 per share | XIn-the-money exerciseAcquired | +15,435 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
On July 1, 2025, the reporting person purchased a promissory note in the principal amount of $14,000 and an accompanying warrant to purchase shares of common stock, par value $0.001 per share (the "Common Stock") at an exercise price of $99.00 per share.
Referenced by the price of 1 transaction in Table II.
- F6
On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").
Referenced by the price of 2 transactions in Table II.
- F8
On October 7, 2022, the reporting person entered into an into Intellectual Property Purchase Agreement (the "IP Purchase Agreement") with the issuer, pursuant to which the reporting person is entitled to certain specified milestone payments, payable in Common Stock, as set forth in the IP Purchase Agreement. Upon the achievement of the first and second milestones contemplated by the IP Purchase Agreement, the reporting person was issued 1,500 shares of Common Stock, pursuant to the terms of the IP Purchase Agreement.
Referenced by the price of 1 transaction in Table I.
Remarks
Note: On May 17, 2024, a 1-for-5 reverse stock split of the Issuer's common stock, par value $0.001 per share (the "Common Stock") was implemented (the "2024 Reverse Split"). On February 25, 2025, a 1-for-20 reverse stock split of the Common Stock was implemented (the "2025 Reverse Split," and together with the 2024 Reverse Split, the "Reverse Stock Splits"). All figures presented in this Form 4 reflect the Reverse Stock Splits.